Last reviewed · How we verify
MBS2320
At a glance
| Generic name | MBS2320 |
|---|---|
| Sponsor | Modern Biosciences Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA (PHASE2)
- Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis (PHASE2)
- Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MBS2320 CI brief — competitive landscape report
- MBS2320 updates RSS · CI watch RSS
- Modern Biosciences Ltd portfolio CI